Delving into the Latest Updates on Cisen Pharmaceutical Ltd. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Infectious Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	5
Neoplasms	4
Endocrinology and Metabolic Disease	3
Nervous System Diseases	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	13
Chemical drugs	1

Top 5 Target	Count

PI3Ks x mTOR	2
APE1(DNA-(apurinic or apyrimidinic site) lyase)	1
PARP(Poly (ADP-Ribose) polymerase)	1
DPP-4(Dipeptidyl peptidase IV)	1
PARP1 x PARP2	1

[Translation] A single-center, open-label, randomized, single-dose, four-period, two-sequence, fully replicated, crossover bioequivalence trial evaluating the investigational formulation, etorizine hydrochloride tablets (50 mg), and the reference formulation, Myona® (50 mg), in healthy adult participants under fasting and postprandial conditions.

主要研究目的：研究空腹和餐后状态下单次口服受试制剂盐酸乙哌立松片（规格：50 mg，辰欣药业股份有限公司生产）与参比制剂盐酸乙哌立松片（妙纳®，规格：50 mg，卫材（中国）药业有限公司持证）在健康成年试验参与者体内的药代动力学，评价空腹和餐后状态下口服两种制剂的生物等效性。次要研究目的：评估受试制剂盐酸乙哌立松片（规格：50 mg）和参比制剂盐酸乙哌立松片（妙纳®，规格：50 mg）在健康成年试验参与者中的安全性。

[Translation]

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation, eperisone hydrochloride tablets (50 mg, manufactured by Chenxin Pharmaceutical Co., Ltd.), and the reference formulation, eperisone hydrochloride tablets (Miaona®, 50 mg, certified by Eisai (China) Pharmaceutical Co., Ltd.), in healthy adult participants under both fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial conditions. Secondary objective: To evaluate the safety of the test formulation, eperisone hydrochloride tablets (50 mg), and the reference formulation, eperisone hydrochloride tablets (Miaona®, 50 mg), in healthy adult participants.

Start Date18 May 2026

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

CTR20261399

/ CompletedNot Applicable

巴瑞替尼片在健康成年参与者餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究

[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study of baricitinib tablets in healthy adult participants in a postprandial state.

主要研究目的：以辰欣药业股份有限公司研制的巴瑞替尼片（规格：4 mg）为受试制剂，以日本イーライリリー株式会社持证的巴瑞替尼片（商品名：オルミエント®Olumiant®，规格：4 mg）为参比制剂，评估健康参与者体内的药代动力学，评价餐后状态口服两种制剂的生物等效性。次要研究目的：评价中国健康参与者单次餐后状态下口服巴瑞替尼片受试制剂和参比制剂后的安全性。

[Translation]

Primary objective: To evaluate the pharmacokinetics of baricitinib tablets (4 mg, developed by Chenxin Pharmaceutical Co., Ltd.) in healthy participants and assess the bioequivalence of the two formulations after a meal, using baricitinib tablets (trade name: Olumiant®, 4 mg, certified by Iriirily Co., Ltd., Japan) as the test formulation. Secondary objective: To evaluate the safety of a single postprandial oral administration of the test and reference formulations of baricitinib tablets in healthy Chinese participants.

Start Date14 May 2026

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

CTR20261401

/ Active, not recruitingNot Applicable

评估受试制剂盐酸吡格列酮片（规格：30 mg）与参比制剂ACTOS®（规格：30 mg）在健康成年试验参与者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验

[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence trial evaluating the investigational formulation pioglitazone hydrochloride tablets (30 mg) and the reference formulation ACTOS® (30 mg) in healthy adult participants in fasting condition.

主要研究目的：研究空腹状态下单次口服受试制剂盐酸吡格列酮片（规格：30 mg，辰欣药业股份有限公司生产）与参比制剂盐酸吡格列酮片（ACTOS®，规格：30 mg，武田テバ薬品株式会社持证）在健康试验参与者体内的药代动力学，评价空腹状态下口服两种制剂的生物等效性。次要研究目的：评估受试制剂盐酸吡格列酮片（规格：30 mg）和参比制剂盐酸吡格列酮片（ACTOS®，规格：30 mg）在健康试验参与者中的安全性。

[Translation]

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation pioglitazone hydrochloride tablets (30 mg, manufactured by Chenxin Pharmaceutical Co., Ltd.) and the reference formulation pioglitazone hydrochloride tablets (ACTOS®, 30 mg, licensed by Takeda Pharmaceutical Co., Ltd.) in healthy trial participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting conditions. Secondary objective: To evaluate the safety of the test formulation pioglitazone hydrochloride tablets (30 mg) and the reference formulation pioglitazone hydrochloride tablets (ACTOS®, 30 mg) in healthy trial participants.

Start Date11 May 2026

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

100 Clinical Results associated with Cisen Pharmaceutical Ltd.

Login to view more data

0 Patents (Medical) associated with Cisen Pharmaceutical Ltd.

Login to view more data

100 Deals associated with Cisen Pharmaceutical Ltd.

Login to view more data

100 Translational Medicine associated with Cisen Pharmaceutical Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

2

Phase 1

Phase 2

5

2

Phase 3

Approved

1

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Fesoterodine Fumarate ( mAChRs )	Pollakisuria More	Phase 3
Sudapyridine ( ATP synthase )	Pulmonary Tuberculosis More	Phase 3
WXSH0102	Candidiasis, Vulvovaginal More	Phase 2
WXSH0176	Colitis, Ulcerative More	Phase 2
WXFL10030390 ( PI3Ks x mTOR )	Advanced Malignant Solid Neoplasm More	Phase 1/2